

## Product datasheet

# Human TYROBP knockout THP-1 cell lysate ab273774

2 Images

### Overview

<b>Product name</b>	Human TYROBP knockout THP-1 cell lysate
<b>Product overview</b>	Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.
<b>Parental Cell Line</b>	THP-1
<b>Organism</b>	Human
<b>Mutation description</b>	Knockout achieved by CRISPR/Cas9; X = 1 bp insertion; Frameshift = 99%
<b>Passage number</b>	<20
<b>Knockout validation</b>	Next Generation Sequencing (NGS)
<b>Reconstitution notes</b>	To use as WB control, resuspend the lyophilizate in 50 µL of LDS* Sample Buffer to have a final concentration of 2 mg/ml. For reducing conditions, we recommend a final concentration of 0.1 M DTT.

*\*Usage of SDS sample buffer is not recommended with these lyophilized lysates.*

### Notes

**Lysate preparation:** Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). *This means that the protein of interest is denatured.* If you require a native form of the protein please use the live cell version - found [here](#). Please refer to our lysis protocol for further details on how our lysates are prepared.

**User storage instructions:** Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

Access thousands of knockout cell lysates, generated from commonly used cancer cell lines.

**[See here for more information on knockout cell lysates.](#)**

Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.

It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our [limited use license](#) and [patent pages](#).

### Tested applications

**Suitable for:** WB

## Properties

**Storage instructions** Store at -80°C. Please refer to protocols.

Components	1 kit
ab280624 - Human TYROBP knockout THP-1 cell lysate	1 x 100µg
ab269602 - Human wild-type THP-1 cell lysate	1 x 100µg

**Cell type** acute monocytic leukemia  
**Disease** Acute Monocytic Leukemia  
**Gender** Male

## Target

**Function** Non-covalently associates with activating receptors of the CD300 family. Cross-linking of CD300-TYROBP complexes results in cellular activation.

**Tissue specificity** Expressed at low levels in the early development of the hematopoietic system and in the promonocytic stage and at high levels in mature monocytes. Expressed in hematological cells and tissues such as peripheral blood leukocytes and spleen. Also found in bone marrow, lymph nodes, placenta, lung and liver. Expressed at lower levels in different parts of the brain especially in the basal ganglia and corpus callosum.

**Involvement in disease** Defects in TYROBP are a cause of polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) [MIM:221770]; also called presenile dementia with bone cysts or Nasu-Hakola disease (NHD). PLOSL is a recessively inherited disease characterized by a combination of psychotic symptoms rapidly progressing to presenile dementia and bone cysts restricted to wrists and ankles. PLOSL has a global distribution, although most of the patients have been diagnosed in Finland and Japan, with an estimated population prevalence of 2x10<sup>-6</sup> in the Finns.

**Sequence similarities** Belongs to the TYROBP family.

**Post-translational modifications** Tyrosine phosphorylated.

**Cellular localization** Membrane.

## Applications

**The Abpromise guarantee** Our **Abpromise guarantee** covers the use of ab273774 in the following tested applications. The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application	Abreviews	Notes
WB		Use at an assay dependent concentration. Predicted molecular weight: 12 kDa. Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.



**Lane 2:** TYROBP knockout THP-1 cell lysate 40  $\mu$ g

Knockout achieved by CRISPR/Cas9; X = 1 bp insertion;  
Frameshift = 99%



### **Our Abpromise to you: Quality guaranteed and expert technical support**

---

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <https://www.abcam.com/abpromise> or contact our technical team.

### **Terms and conditions**

---

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors